SecBot SecBot
PRESS-RELEASE ·Filed Nov 13, 2026

IMCC

IM Cannabis Corp.
BEARISH
Impact 6/10
Horizonweeks Processed3d 22h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

Monitor the definitive agreement for the SDI acquisition and the company's ability to fund operations given the widening losses and low market cap. The sale of European operations may improve equity by C$3M, but the core Israeli cannabis business is shrinking.

DirectionBearish
Confidencehigh
Horizonweeks
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

IM Cannabis reported Q3 2026 revenue of C$1.65M, down 68% from C$5.08M a year ago, and a net loss of C$7.08M versus a C$3.87M loss in Q3 2025. The results reflect the sale of European operations (Adjupharm GmbH) and a focus on Israeli medical cannabis, with a non-binding agreement to acquire a 51% stake in a Polish drone company (SDI).

Key Facts

  • Q3 2026 revenue C$1.65M vs C$5.08M in Q3 2025 (down 68%)
  • Q3 2026 net loss C$7.08M vs C$3.87M in Q3 2025 (loss nearly doubled)
  • Gross loss of C$35,000 in Q3 2026
  • First nine months 2026 revenue C$8.96M vs C$15.77M (down 43%)
  • First nine months 2026 net loss C$13.93M vs C$3.88M (loss more than tripled)
  • Completed sale of European operations (Adjupharm GmbH) on Sep 29, 2026 for C$3M advance payment and assumption of up to C$9.4M liabilities
  • Non-binding agreement to acquire 51% stake in Space Defense Innovations LLC (SDI), a Polish drone company
  • Market cap $1M; normal daily move 9.9%

Financial Impact

Revenue decline of 68% YoY; net loss increased by 83% YoY; gross loss of C$35,000

revenuenet incomegross margin

Risk Factors

  • Revenue decline of 68% YoY signals severe operational contraction
  • Net loss nearly doubled despite divestiture of European operations
  • Going concern risk given $1M market cap and negative cash flow trajectory
  • Non-binding SDI acquisition adds execution risk and potential dilution
  • Nasdaq continued listing compliance risk

Market Snapshot

Exchange
Nasdaq
Sector
Medicinal Chemicals & Botanical Products
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302939384

Track record

23 reports on IMCC

Performance horizon

9 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +82.97% at T+60 after the Aug 13, 2026 report. 11 of 11 went positive at some point.

Filters
  1. Nov 17, 2026today SC 13G Neutral 4/10 Entry $0.4995 Now $0.4800 −3.90% settles Dec 16
  2. Nov 13, 20263d ago 6-K Bearish 6/10 Entry price pending
  3. Nov 13, 20263d ago Press Release Bearish 6/10 Viewing Entry $0.5750 Now $0.4800 +16.52% settles Dec 15
  4. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.5800 Now $0.4800 −17.24% settles Dec 15
  5. Nov 4, 202612d ago 6-K Bearish 6/10 Entry $0.5934 Now $0.4800 +19.11% settles Dec 4
  6. Nov 4, 202612d ago Press Release Bearish 5/10 Entry $0.5934 Now $0.4800 +19.11% settles Dec 4
  7. Oct 21, 202627d ago EFFECT Neutral 4/10 Entry $1.19 Now $0.4800 −59.66% settles Nov 18
  8. Oct 2, 20266w ago 6-K Mixed 6/10 Entry $1.94 to $0.7675 Now $0.4800 −75.26% ▼ −60.44% −57.86% vs SPY
  9. Sep 25, 20267w ago 6-K Bearish 6/10 Entry $2.48 to $0.8400 Now $0.4800 +80.65% ▲ +66.13% +66.10% vs SPY
  10. Sep 24, 20267w ago 424B5 Bearish 7/10 Entry $3.18 to $0.9250 Now $0.4800 +84.91% ▲ +70.91% +70.49% vs SPY
Showing 10 of 23

US Market Status

Market Open · Closes in 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026